Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Predictive Biomarkers Can Be Supported By Two Well-Conducted Retrospective Studies - FDA Advisors

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee considers biomarker validation in context of KRAS biomarker for the cancer agents Vectibix and Erbitux
Advertisement

Related Content

FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill
FDA, CMS Joint Guidance On Studies Using Cancer Biomarkers Sought In Bill
FDA Seeks Input On Acceptable Trial Design For Assessing Predictive Biomarkers
FDA Seeks Input On Acceptable Trial Design For Assessing Predictive Biomarkers

Topics

Advertisement
UsernamePublicRestriction

Register

PS067133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel